88 related articles for article (PubMed ID: 10601089)
21. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.
Swahn ML; Johannisson E; Daniore V; de la Torre B; Bygdeman M
Hum Reprod; 1988 Oct; 3(7):915-21. PubMed ID: 2846630
[TBL] [Abstract][Full Text] [Related]
22. Endometrial thickness and oestradiol concentration in women with bleeding complaints during use of Norplant implants.
Faúndes A; Alvarez F; Brache V; Cochón L
Hum Reprod; 1998 Jan; 13(1):188-91. PubMed ID: 9512255
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
24. Concentration-dependent mechanisms of ovulation inhibition by the progestin ST-1435.
Lähteenmäki PL; Lähteenmäki P
Fertil Steril; 1985 Jul; 44(1):20-4. PubMed ID: 3924666
[TBL] [Abstract][Full Text] [Related]
25. Bone turnover markers in women participating in a dose-finding trial of a contraceptive vaginal ring releasing Nestorone and estradiol.
Tiedeken M; Westhoff CL; Cohen A; Cremers S; Sitruk-Ware R; Blithe DL;
Contraception; 2019 Jun; 99(6):329-334. PubMed ID: 30871934
[TBL] [Abstract][Full Text] [Related]
26. Intracervical release of ST-1435 for contraception.
Kurunmäki H; Toivonen J; Lähteenmäki PL; Luukkainen T
Contraception; 1984 May; 29(5):411-21. PubMed ID: 6430641
[TBL] [Abstract][Full Text] [Related]
27. Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.
Jensen JT; Edelman AB; Chen BA; Archer DF; Barnhart KT; Thomas MA; Burke AE; Westhoff CL; Wan LS; Sitruk-Ware R; Kumar N; Variano B; Blithe DL
Contraception; 2018 May; 97(5):422-427. PubMed ID: 29409834
[TBL] [Abstract][Full Text] [Related]
28. Subdermal progestin implant (Nestorone) in the treatment of endometriosis: clinical response to various doses.
Ylänen K; Laatikainen T; Lähteenmäki P; Moo-Young AJ
Acta Obstet Gynecol Scand; 2003 Feb; 82(2):167-72. PubMed ID: 12648180
[TBL] [Abstract][Full Text] [Related]
29. The use of biodegradable norethisterone implants as a 6-month contraceptive system.
Rivera R; Gaitan JR; Ortega M; Flores C; Hernandez A
Fertil Steril; 1984 Aug; 42(2):228-32. PubMed ID: 6745456
[TBL] [Abstract][Full Text] [Related]
30. Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women.
Sivin I; Croxatto H; Bahamondes L; Brache V; Alvarez F; Massai R; Schechter J; Ranta S; Kumar N; Wu E; Tejeda AS; Reyes V; Travers E; Allen A; Moo-Young A
Contraception; 2004 Feb; 69(2):137-44. PubMed ID: 14759619
[TBL] [Abstract][Full Text] [Related]
31. Effects of long-term low-dose mifepristone on reproductive function in women.
Croxatto HB; Kovács L; Massai R; Resch BA; Fuentealba B; Salvatierra AM; Croxatto HD; Zalányi S; Viski S; Krenács L
Hum Reprod; 1998 Apr; 13(4):793-8. PubMed ID: 9619526
[TBL] [Abstract][Full Text] [Related]
32. Effects of intermittent antiprogestin RU486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation.
Kekkonen R; Croxatto HB; Lähteenmäki P; Salvatierra AM; Tuominen J
Hum Reprod; 1995 Feb; 10(2):287-92. PubMed ID: 7769050
[TBL] [Abstract][Full Text] [Related]
33. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
[TBL] [Abstract][Full Text] [Related]
35. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium.
Swahn ML; Bygdeman M; Cekan S; Xing S; Masironi B; Johannisson E
Hum Reprod; 1990 May; 5(4):402-8. PubMed ID: 2113927
[TBL] [Abstract][Full Text] [Related]
36. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
37. Vaginal rings for contraception in lactating women.
Massai R; Díaz S; Jackanicz T; Croxatto HB
Steroids; 2000; 65(10-11):703-7. PubMed ID: 11108880
[TBL] [Abstract][Full Text] [Related]
38. Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol.
Archer DF; Thomas MA; Conard J; Merkatz RB; Creasy GW; Roberts K; Plagianos M; Blithe D; Sitruk-Ware R
Contraception; 2016 Jan; 93(1):58-64. PubMed ID: 26408374
[TBL] [Abstract][Full Text] [Related]
39. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
Croxatto HB; Salvatierra AM; Romero C; Spitz IM
J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
[TBL] [Abstract][Full Text] [Related]
40. Nestorone: clinical applications for contraception and HRT.
Sitruk-Ware R; Small M; Kumar N; Tsong YY; Sundaram K; Jackanicz T
Steroids; 2003 Nov; 68(10-13):907-13. PubMed ID: 14667982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
